Moderate alcohol consumption down-regulates 11β-hydroxysteriod dehydrogenase type-1 (11β-HSD1) in the liver of high-fat-diet fed rats by Devi, Shayal A.
i  
  
 
 
 
 
Moderate alcohol consumption down-regulates 
11β-hydroxysteriod dehydrogenase type-1 (11β-HSD1) 
in the liver of high-fat-diet fed rats 
 
 
Shayal Arishma Devi 
School of Science and Health 
Western Sydney University 
 
 
Thesis Submitted to Western Sydney University in Partial Fulfilment of the 
Requirements for the Degree of 
 
 
Master of Research 
 
 
Supervisor: Dr. Srinivas Nammi 
ii  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedication 
 
To my family- backbone for everything I do. 
iii  
Acknowledgements 
 
This thesis would have not been accomplished without the help of countless 
individuals that provided assistance during various stages of this project. I would like 
to extend my acknowledgments and appreciation to the following people that have 
helped me in many aspects of my work. 
Firstly, I would like to thank my supervisor, Dr Srinivas Nammi. This project 
was designed and driven by his approach to biomedical research and I could have not 
completed without your support, time, knowledge, experience and patience. I would 
like to thank you for always understanding the roller-coaster life has put me through 
and always provided me with guidance and advice. Thank you for all the opportunities 
you have given during my time of study. I would also like to extend my appreciation 
to all the students under the supervision of Dr Srinivas Nammi, in particular Vamsi 
Krishna and Hardik Ghelani who have helped me get through a new laboratory setting 
and always provided me with the correct procedures in performing a set task and more 
importantly being there as friends. 
To Kajaal & Adeline, thank you both for being there since day one of MRes 
and all your support during the time of our master’s completion. To my best friends 
Rajaa and Serena for always being there especially in times when I was not at my best. 
To my family: mummy, papa, Ash bhaiya and Kaylene Bhabi, I really appreciate 
you all not leaving my side and thank you for your never-ending support, 
love and encouragement to reach my goals. 
 
Finally, to everyone who has ever crossed my path during my journey of 
masters and whether you are the lab tech, people who worked alongside in the lab or 
those who listened to the boring talk of what my project is about, I thank each and 
every one of you. 
iv  
 
 
 
 
Statement of Authenticity 
 
 
This thesis is submitted in fulfilment of the requirements of the Master of Research 
course at the School of Science and Health, Western Sydney University. The work 
presented in this thesis is, to the best of my knowledge and belief, original except as 
acknowledged in the text. I hereby declare that I have not previously submitted this 
material, either in whole or in part, for a degree at this or any other institution. 
 
 
…  
 
Shayal Devi 
June 2018 
v  
 
 
Table of Contents 
Title Page ...................................................................................................................... i 
Dedication .................................................................................................................... ii 
Acknowledgements ................................................................................................... iii 
Statement of Authentication… ................................................................................... iv 
List of Figures ........................................................................................................ viii 
List of Tables ............................................................................................................viii 
List of Abbreviations ...................................................................................................ix 
Abstract ....................................................................................................................... x 
CHAPTER-1: Introduction and Review of Literature ..................... 1 
1.1 Introduction… ...................................................................................................... 2 
1.2 Non-Alcoholic Fatty Liver Disease .................................................................... 3 
1.2.1 Pathophysiological Stages of Non-Alcoholic Fatty Liver Disease ................ 4 
1.2.2 Occurrence of NAFLD ................................................................................... 5 
1.2.3 Prevalence of NAFLD .....................................................................................7 
1.2.4 Pathogenesis of NAFLD ................................................................................ 8 
1.2.5 Diagnosis of NAFLD ................................................................................... 11 
1.2.6 Treatment Options of NAFLD… ................................................................... 11 
1.3 Glucocorticoids ................................................................................................... 13 
1.3.1 The Role of 11β-HSD1 in the Generation of Active Glucocorticoids………14 
1.3.2 Relevance of 11β-HSD1 to NAFLD and Cushing’s syndrome ..................... 16 
vi  
1.4 Alcohol ............................................................................................................... 17 
1.4.1 Pharmacokinetics of Alcohol ........................................................................ 17 
1.4.2 Pharmacodynamics of Alcohol ......................................................................... 19 
1.4.3 Biological Effects of Light-to-Moderate Alcohol Consumption… ................. 20 
1.5 Gaps in Literature ................................................................................................ 22 
1.6 Hypothesis and Objectives .................................................................................. 23 
CHAPTER-2: Materials and Methods ................................................................ 24 
2.1 Chemicals Used… ............................................................................................ 25 
2.2 Equipment Used… ............................................................................................ 25 
2.3 Preparation of Reagents ....................................................................................... 25 
2.4 Dosage Selection of the Treatments and Sample Size ....................................... 29 
2.4.1 Dosage Selection ............................................................................................ 29 
2.4.2 Sample Size ....................................................................................................... 30 
2.5 Evaluation of the Effects of Light and Moderate Alcohol in High Fat Diet-Fed 
Rats (in vivo studies) .................................................................................................. 31 
2.5.1 The Effects of Light and Moderate Alcohol Treatment on Protein Expression of 
11β-HSD1 in the Liver of HFD-Fed Rats ................................................................ 32 
2.5.2 The Effects of Light and Moderate Alcohol Treatment on the Enzyme Activity 
of 11β-HSD1 in the Liver of HFD-Fed Rats ............................................................ 34 
2.5.3 The Effects of Light and Moderate Alcohol Treatment on Serum and Liver 
Corticosterone Levels in HFD-Fed Rats .................................................................... 36 
vii  
2.5.4 Data and Statistical Analysis ........................................................................... 37 
CHAPTER-3: Results ............................................................................................ 38 
3.1 The Effects of Light and Moderate Alcohol Treatment on Protein Expression of 
11β-HSD1 in the Liver of HFD-Fed Rats ............................................................... 39 
3.2 Effects of Light and Moderate Alcohol Treatment on the Enzyme Activity of 
11β-HSD1 in the Liver of HFD-Fed Rats ............................................................... 40 
3.3 Effects of Light and Moderate Alcohol Treatment on Serum and Liver 
Corticosterone Levels in HFD-Fed Rats .................................................................... 41 
CHAPTER-4: Discussion .................................................................................. 43 
CHAPTER-5: Conclusions, Limitations and Future Directions .....................47 
5.1 Conclusions ........................................................................................................ 48 
5.2 Limitations and Future Directions........................................................................ 48 
viii 
List of Figures 
 
 
 
Figure 1. Visual representation of the progression of NAFLD 
 
Figure 2. The catalytic action of the 11β-HSD1 in the endoplasmic reticulum. 
Figure 3. The protein expression of 11β hydroxysteriod dehydrogenase (11β-HSD1) 
in liver. 
Figure 4. Oxo-reductase activity of 11β-HSD1 in liver. 
Figure 5. Serum (A) and liver (B) corticosterone levels. 
 
 
List of Tables 
 
Table 1. Literature summary of different types of studies that found protective 
effects of light and moderate alcohol. 
Table 2. Resource equation method for sample size determination 
Abbreviations 
ix 
 
 
 
Abbreviations Meaning 
11β-HSD1 11 beta-hydroxysteriod dehydrogenases type 1 
ACHe Acetylcholinesterase 
ADH Alcohol dehydrogenase 
Bo Maximum binding 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol tetra-acetic acid 
ELISA Enzyme-linked immunosorbent assay 
H6PDH Hexose-6-phospate dehydrogense 
HFD High-fat-diet 
NAFLD Non-alcoholic fatty liver disease 
NASH Non-alcoholic steatosis 
NSB Non- specific binding 
PBS Phosphate-buffered saline 
SDS Sodium dodecyl sulfate 
TBST Tris-buffered saline + tween20 
x 
 
 
Abstract 
 
Obesity is one of the leading cause metabolic disorders in the western-industrialised 
countries. Metabolic disorders such as obesity, insulin resistance and non-alcoholic 
fatty liver disease is caused by the high-fat-diet intake in those population. The excess 
fat accumulation in the body causes alterations in various metabolic pathways, one of 
which is the conversion active glucocorticoids to inactive glucocorticoids. Although 
there are several studies that convey the effect of heavy alcohol consumption is linked 
with the pathogenesis of metabolic disorders and alcoholic fatty liver disease, the 
effect of light-to-moderate alcohol consumption is largely unknown. A number of 
epidemiological studies has demonstrated that regular light-moderate alcohol 
consumption lowers the risk of life threatening diseases such as cardiovascular disease 
and non-alcoholic fatty liver disease (NAFLD). Thus, in this study we investigated the 
effect of chronic light-to-moderate alcohol consumption in high-fat diet-fed rats on the 
hepatic regulation of 11β-HSD1 protein expression and its enzyme activity together 
with measurements of serum and hepatic corticosterone levels. The results 
demonstrated that light-to-moderate alcohol consumption down-regulated the 
expression of 11β-HSD1 protein in the liver together with decreased enzyme activity. 
In parallel, light-to-moderate alcohol also lowered the serum and liver corticosterone 
levels in rats fed with high fat diet. In conclusion, the present study demonstrated that 
chronic light-moderate alcohol consumption down-regulated 11β-HSD1 protein 
expression and decreased enzymatic activity in the liver of HFD-fed rats, which was 
associated with a reduction in circulating and liver corticosterone levels. Thus, the 
present study provides mechanistic evidence for the earlier epidemiological studies 
that indicate light-to-moderate alcohol consumption lowers the risk of development of 
metabolic syndrome leading to NAFLD, at least in part, via targeting 11β-HSD1. 
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1.1 Introduction 
 
Even though heavy alcohol consumption has been linked in the pathogenesis of 
metabolic disorders and alcoholic fatty liver disease (W and Suthat, 2006, Lieber, 
2004), there are several epidemiological studies that have reported low risk of 
mortality and morbidity from life threatening diseases in regular light-to-moderate 
alcohol consumption (Nova et al., 2012, Camargo et al., 1997, Duffy, 1995, Doll et 
al., 1994, de Groot and Zock, 1998, Brenner, 2000, Hoffmeister et al., 1999). In some 
human studies, there is an association between lowered risk of the development of 
insulin resistance and light-to-moderate alcohol consumption (Bell et al., 2000, 
Greenfield et al., 2003) and type 2 diabetes (Wannamethee et al., 2003). It also showed 
that it provides protection against the risk of major cardiovascular disease events such 
as myocardial infarction and coronary artery disease in healthy population (Berger et 
al., 1999, Gaziano et al., 2000, Gaziano et al., 1993) and in patients with type 2 diabetes 
(Diem et al., 2003, Solomon et al., 2000), hypertension (Beulens et al., 2007, Malinski 
et al., 2004), myocardial infarction (Mukamal et al., 2001, Muntwyler et al., 1998), 
and non-alcoholic fatty liver disease (NAFLD) (Hamaguchi et al., 2012, Moriya et al., 
2011, Cotrim et al., 2009, Dixon et al., 2001). Recent animal studies have also 
demonstrated that light-to-moderate alcohol treatment reduces the development of 
NAFLD through improved liver lipid metabolism in normal (Nammi and Roufogalis, 
2013) and in high-fat diet fed rats (Zhu et al., 2008) and in genetically obese ob/ob 
mice (Kanuri et al., 2016, Fromenty et al., 2009). 
Furthermore, there is significant evidence suggesting that glucocorticoids play 
an important role in the pathogenesis of NAFLD (Ahmed et al., 2012, Tarantino and 
Finelli, 2013). Glucocorticoids are hormones that is released by adrenal cortex which 
provides protection to the body in fasting state and it also functions opposite to insulin 
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(Chapman et al., 2013). Though the circulating levels of tissue glucocorticoids are 
normal, it is known that excess glucocorticoids at tissue level produce metabolic 
dyslipidaemia and insulin resistance (Chapman et al., 2013). Therefore, the actions of 
these hormones are dependent to the local regeneration of their active forms from their 
inactive forms (Chapman et al., 2013). The enzyme 11β-hydroxysteriod 
dehydrogenase 1 (11β-HSD1) is the principal enzyme that converts inactive 
glucocorticoids into bioactive forms and it is considered as a main amplifier of 
glucocorticoid activity at tissue level (Chapman et al., 2013). In a 2007 study 
conducted by Nammi et al, showed that prenatal heavy alcohol intake in rats 
demonstrated glucose intolerance, insulin resistance and increased fat and expression 
of 11β-HSD1 in adulthood (Nammi et al., 2007). However, the role of 11β-HSD1 in 
the development of fatty liver disease remains largely unknown. The hexose-6- 
phosphate dehydrogenase (H6PDH) determines the reaction direction of 11β-HSD1. 
Thus, there is a physical and functional interaction between H6PDH and 11β-HSD1 
and these two enzymes copurify. H6PDH generates the high energy that is required 
for 11β-HSD1 to function proficiently as a reductase (Chapman et al., 2013). Thus, if 
there is high expression of H6PDH there will also be a high expression of 11β-HSD1 
(Chapman et al., 2013). 
1.2 Non-alcoholic fatty liver disease 
 
Non-alcoholic fatty liver disease is one of the world’s important disease to be 
researched. NAFLD occurs in the absences of alcohol intake, genetic and autoimmune 
mechanisms, it consists of histological changes from hepatic steatosis to cirrhosis 
(Dyson et al., 2014, Nassir and Ibdah, 2014). Majority of the patients with NAFLD 
start off with the simple steatosis and that may progress to non-alcoholic steatohepatitis 
(NASH). Moreover, if left untreated it may further lead to fibrosis, 
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cirrhosis and eventually to liver failure. Metabolic syndromes such as obesity, 
dyslipidaemia, hypertension and insulin resistance are strongly associated with 
NAFLD, therefore it shows the hepatic manifestation of these metabolic syndrome 
(Younossi et al., 2016). Furthermore, excessive visceral adiposity, insulin resistance 
and dyslipidaemia are strongly linked and presented to the contribution towards the 
pathogenesis of NAFLD. Although the management of these risk factors remain the 
pillar of NAFLD treatment, the increase in the worldwide prevalence of obesity and 
diabetes due to changing lifestyle contributes to the future burden of the final stage of 
NAFLD (Smith and Adams, 2011). 
 
 
1.2.1 Pathophysiological stages of non-alcoholic fatty liver disease 
 
NAFLD identifies a series of conditions caused by accumulation of fat within the liver 
cells. It is often divided into four stages as shown in figure 1 for the ease of diagnosis 
(Alba and Lindor, 2003, Angulo, 2002). 
Stage 1-Non-alcoholic fatty liver/Steatosis: Steatosis also known as fatty changes, is 
the process where there is an abnormal retention of excess lipids within the cells. At 
this stage, fatty liver does not cause any scarring or problems to the liver. However, if 
left unmanaged it can and will progress to more serve stages of NAFLD. 
Stage 2-Non-alcoholic steatohepatitis (NASH): NASH is more serve than hepatic 
steatosis as it does not only have excess accumulation of fat in the liver cells, it also 
causes inflammation of the liver. 
Stage 3- Fibrosis: The formation of scar tissues (fibrosis) within the liver is caused by 
development of persistent hepatitis and steatohepatitis. At the initial development of 
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fibrosis, the liver continues to function appropriately as this is a process that is slow 
and takes time to develop into further stages of NAFLD. 
Stage 4- Cirrhosis: At this stage of NAFLD, healthy liver tissues are replaced by a lot 
of fibrosis and the structure/function of the liver is severely damaged. Moreover, like 
many other liver conditions, severe cirrhosis in NAFLD may lead to liver failure or 
hepatic carcinoma. 
 
 
Figure 1. Visual representation of the progression of NAFLD. 
 
 
 
1.2.2 Occurrence of NAFLD 
 
The occurrence and progression of NAFLD are complex and it is not completely 
understood. It is known to be associated with many different acquired conditions such 
as insulin resistance (also known as syndrome X), metabolism inaccuracies, existing 
medical conditions or surgeries linked with weight loss, and even various toxins and 
drugs. Furthermore, provides evidence that it is in-fact multifunctional (Sass et al., 
2005). 
In many cases, NAFLD is linked to the “Western lifestyle” which is the 
imbalance of the nutrient intake i.e. cheap processed food are available and interrelated 
with sedentary lifestyle and reduced physical activity. However, genetics also play an 
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important role, it helps in determining high risk individuals of NAFLD and for its 
progression. 
1.2.2.1 Genetic factors of NAFLD 
 
There are a number of studies that have shown the role of genetic predisposition in 
NAFLD. Different ethnicities play a role in occurrence of NAFLD, this can be 
explained based on difference in diet and/ or socioeconomic factors in NAFLD 
progression. Epidemiological studies convey that there is a greater incidence of NASH 
in the Hispanic origin in US population in relation to whites and low rate of incidence 
in the African Americans (Browning et al., 2004, Bugianesi et al., 2005). Another 
group at high risk for development of NAFLD is the South Asian population 
(Amarapurkar et al., 2007, Fan et al., 2007). Australia being a multicultural country 
need to use these populations as genetic markers to identify NAFLD progression. 
In the past studies, a sample population with existing NAFLD was obtained 
and was used to conduct genome scans to determine gene variants that are more 
common in the patients with NAFLD when compared to normal population. In a 2008 
study by Romeo et al, showed the differences in the gene variance in different ethnic 
groups, a gene called PNPLA3 is shown to be linked with the different propensity to 
NAFLD (Romeo et al., 2008). In a 2007 study by Osterreicher et al, tested single 
nucleotide polymorphism (SNP) and showed that some population groups displayed 
variants in the genes which caused implication in the lipid metabolism regulation 
(Osterreicher and Brenner, 2007). 
1.1.2.2 Environmental factors of NAFLD 
 
The generation and accumulation of intrahepatic lipids is closely associated with 
environmental factors such as the life style and choice of diet (Zivkovic et al., 2007). 
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Studies shows that a major contribution to hepatic steatosis are the dietary fats such as 
trans unsaturated fats (Alkhouri et al., 2009). However, there is a decrease in the 
intrahepatic lipid accumulation and possible improvement in the postprandial 
triglyceride levels when monounsaturated lipids such as oleic acid is consumed. This 
is achieved by their ability to increase peroxisomal activity which further decreases 
damage by reactive oxygen species (Zandbergen and Plutzky, 2007). 
Another dietary factor that contributes to hepatic steatosis is the 
monosaccharide fructose. In a controlled study, it showed that beverages that was 
sugar sweetened was independently linked to obesity (Abid et al., 2009). Furthermore, 
the total fructose consumption was linked with general NAFLD and in particularly 
with NASH (Ouyang et al., 2008). Moreover, if there is an excess caloric intake, it 
leads to obesity and insulin resistance. All these factors contribute to the development 
of NAFLD by directly increasing the FFA flux and indirectly increasing the de nova 
lipogenesis to the liver through the inhibition of lipolysis (W and Suthat, 2006). 
1.2.3 Prevalence of NAFLD 
 
In modern Australians there is high resemblance in terms of being overweight with 
communities in the North and South America, Southern Europe, Japan, China, Korea 
India, and other Asia-Pacific countries (Younossi et al., 2016). According to the 
Australian statistics bureau, approximately 62.8% adults were obese/overweight in 
Australia. Although obesity is 25-year old phenomenon with the increase in evidence 
that there is a high (70-90%) chance of hereditary obesity which is also found in type 
2 diabetes and NASH, Australian prevalence is only going to increase in the next 20 
years (Younossi et al., 2016). In general population from different countries it affects 
about 10-24% (Dyson et al., 2014). However as mentioned previously, the prevalence 
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of NALFD will significantly increase to 57.5-74% in obese individuals, in patients 
with type 2 diabetes 28-55% and in patients with hyperlipidaemia 20-92% (Bellentani 
et al., 2000). Over the past years the prevalence of the NAFLD has increased 
particularly in the Western countries, which also shows an increase in the prevalence 
of obesity and diabetes and that it occurs in all age groups despite of any existing 
diseases. 
1.2.4 Pathogenesis of NAFLD 
 
Two-hit hypothesis is often used to describe the pathogenesis of NAFLD. The 
accumulation of hepatic triglyceride/steatosis is the “first-hit” which increases the 
vulnerability of liver to injury mediated by the “second hit” such as inflammatory 
cytokines, oxidative stress and mitochondrial dysfunction which further leads to 
steatohepatitis or fibrosis (Day and James, 1998). However, understanding the role of 
free fatty acids in the process of promoting liver injury leads to some modifications of 
the theory. In obesity and insulin resistance, there is an influx of FFAs to the liver due 
to the hepatic fat accumulation. Furthermore, these FFAs go under either of the two 
processes; β-oxidation or are esterified with glycerol to form triglycerides hence leads 
to hepatic fat accumulation (Day and James, 1998). Currently, there is a number of 
evidence that show that there is a direct relation between FFAs and the cause of toxicity 
by the activation of the inflammatory pathways or by the increase in the oxidative 
stress (Feldstein et al., 2004). Furthermore, theses toxic effects of the unesterified FFA 
may provide protection from hepatic lipid accumulation (Yamaguchi et al., 2007). 
Moreover, there is an addition of a “third-hit” which reflect incompetent hepatocyte 
proliferation (Jou et al., 2008). The dead cells are replaced by matured hepatocytes and 
reconstitute normal tissue function in a healthy liver (Jou et al., 2008).However, the 
replication of matured hepatocyte is inhibited in oxidative stress 
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which is a common feature of the NAFLD pathogenesis which then results in an 
enlargement of hepatic progenitor cells (oval cells) (Roskams et al., 2003). The 
activation of these oval cells may cause hepatic carcinogenesis (Roskams et al., 2003). 
Furthermore, the development of fibrosis/cirrhosis is determined by the efficacy of 
hepatocyte regeneration in chronic liver injury. Proliferation of hepatocyte progenitors 
and cell death in NAFLD pathogenesis is usually present in the proposed “third hit” 
(Jou et al., 2008). 
1.2.4.1 Hepatic steatosis and lipid accumulation 
 
Imbalance in lipid flux results in hepatic steatosis. Increase in the lipid storage from 
the increased adipose tissue lipolysis and/or high fat diet intake, increased hepatic de 
novo lipid synthesis, decrease in lipid oxidation and VLDL secretions are all 
contributing factors of towards the accumulation of hepatic fat (Tilg and Moschen, 
2010). The FFA oxidation pathway is used for energy formation from the lipids in the 
liver, which then is inhibited by the rise of malonyl-CoA, as a result of insulin 
facilitated activation of sterol regulatory element binding protein- 1c (Browning et al., 
2004). Therefore, the accumulation of hepatic fat can occur as a result of increased fat 
synthesis, fat delivery or decrease in exportation of fat or in fat oxidation (Postic and 
Girard, 2008). The pathogenesis of NAFLD can also be a result of modern diets that 
contain high levels of trans-fatty acid (usually found in processed oils) and a 
commonly used sweetener in beverages; fructose. Furthermore, high fructose diet is 
linked to insulin resistance in humans and cause more severe hepatic inflammation and 
fibrosis in patients with NAFLD (Stanhope et al., 2009, Ouyang et al., 2008). 
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1.1.4.2 Free fatty acids and inflammatory cytokines 
 
The activation of the Ikk-b/NF-kB signalling pathway mediates the chronic hepatic 
inflammation which is closely associated in the presence of steatosis. The increase in 
NF-kB activity in rodent models with high fat diet induced steatosis is linked with the 
increase in inflammatory cytokines (Cai et al., 2005). A direct activation of the ikk- 
b/NF-kB pathway in hepatocytes can occur via FFAs which enables further 
mechanism by which the central obesity can increase hepatic FFA further contributing 
to the inflammation of the liver (Feldstein et al., 2004). 
1.1.4.3 Mitochondrial dysfunction and oxidative stress 
 
There is a well establishment of the role mitochondrial dysfunction and oxidative stress 
in NASH (Chalasani et al., 2004). In normal liver, beta oxidation takes place in the 
mitochondria whereas in patients with NAFLD this process is exhausted as the result 
of increased FFA load and continued increasing of ROS (Petta et al., 2009, Day, 2002). 
There is ploughing activation of the inflammatory pathways and mitochondrial damage 
due to ROS induced oxidative stress (Day, 2002). There are structural mitochondrial 
abnormalities in patients with NASH which leads to reduction in mitochondrial 
respiratory chain activation (Pérez‐Carreras et al., 2003). 
1.1.4.4 Genetic predisposition 
 
In patients with obesity and insulin resistance hepatic steatosis is common and only 
some progress into NASH and cirrhosis, which suggests that there is important 
interplay between environmental factors and genetic predisposition (Petta et al., 2009). 
The development of NASH may be due to the increase in polymorphisms in the genes 
that relate to lipid metabolism, oxidative stress and insulin resistance (de Alwis and 
Day, 2007). Studies conducted by Guo et al., and Sermasathansawadi et al., showed 
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that single nucleotide polymorphisms influenced the development of fibrosis in other 
liver diseases, in particularly chronic hepatitis C (Guo et al., 2009, 
Sermasathanasawadi et al., 2008). NASH studies have further demonstrated 
polymorphisms in the angiotensinogen and TGF-β1 genes to be associated with 
advanced hepatic fibrosis in obese patients (Dixon et al., 2003). 
1.2.5 Diagnosis of NAFLD 
 
As with most of other types of chronic liver disease, patients with NAFLD are 
asymptomatic (Sass et al., 2005). After the exclusion of other chronic liver diseases 
and hepatitis C, NAFLD is common cause for unexplained continual elevation of the 
ALT levels (Clark et al., 2003). The symptoms of NAFLD is usually nonspecific which 
can include right upper quadrant abdominal pain and fatigue (Reid, 2001). Obesity is 
one of the most common abnormality upon physical examination, occurrence results 
in 40-100% of the patients in some cross-sectional studies (Sass et al., 2005). Some 
studies have shown that about 75% of patients has been reported with hepatomegaly 
(Hoang et al., 2008). 
1.2.6 Treatment options of NAFLD 
 
Currently there are no approved single therapy in terms of the treatment of NAFLD, 
with a growing consensus of only patients with NASH require treatment and should 
be the targets of future clinical trials. There are patients with other forms of the liver 
diseases that exist and are at risk for other complications of metabolic syndrome, and 
the treatment options for those underlying metabolic syndromes should be referred. 
Although there are some pharmaceutical drugs used for the treatment of NASH, the 
initial focus of the management of the issue should be lifestyle modification and the 
reversal of conditions that are linked with NAFLD (Kadayifci et al., 2007). 
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1.2.6.1 Weight loss management and exercise 
 
Changes in the lifestyle should include but is not subjected to nutritional counselling 
whether is it is with or without exercise. The decrease of white adipose tissue will also 
decrease the insulin resistance as a pathophysiological basis of weight reduction results 
(Kadayifci et al., 2007). Improvement of insulin resistance on NAFLD can be due to 
exercise which improves muscular insulin sensitivity. There is significant decrease in 
the ALT values in patients with diagnosed NAFLD when they are placed on a strict 
calorie-restricted diets in addition or exclusion of exercise (Kadayifci et al., 2007). 
Furthermore, there are some researchers who have studied the use of 
medication for weight loss. In a clinical trial, it showed that the use of orlistat, an 
enteric lipase inhibitor, showed a decrease in the mean of the body weight of 10.3kg. 
In obese patients with NASH there was a significant decrease in the serum 
transaminase levels (Brolin, 2002). Furthermore, another study indicated that patients 
undergoing laparoscopic adjustable gastric banding resulted in mean weight loss of 34 
kg and it is showed that NASH is resolved in 82% of these patients (Kral et al., 2004). 
1.2.6.2 Treatment options for insulin resistance 
 
Due the presence of insulin resistance in most patients with NAFLD, drugs that 
enhance the insulin action is more of a logical approach (Caldwell et al., 2006, Ahima, 
2007). In some pilot studies, drugs such as meatformin, rosiglitazone, thiazolinediones 
and pioglitazone have been tested. Metformin is one of the most tested drugs in the 
studies, which mainly involved less than 30 patients (Bugianesi et al., 2005, 
Schwimmer et al., 2005). There is one study that showed improved liver functions in 
the patients with NAFLD. In a 6-month long study in 2006 by Belfort et al showed 
pioglitazone when compared with placebo has a significant effect on the severity of 
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NASH (Belfort et al., 2006). Furthermore, the regulation of energy homeostasis and 
food intake is influenced in regard to the emerging role of glucagon like peptide-1 
(GLP-1). These receptors stimulate insulin and suppresses secretion which results in 
in some beneficial effects of the glucose homeostasis (Drucker and Nauck, 2006). 
1.3 Glucocorticoids 
 
There is substantial information suggesting that glucocorticoids play an important role 
in the pathogenesis of NAFLD (Ahmed et al., 2012, Tarantino and Finelli, 2013). 
Excess tissue glucocorticoid levels elicit visceral obesity and the metabolic syndrome, 
despite their circulating levels are normal. Glucocorticoid action in target tissues 
depends on the local regeneration of their active forms (cortisol or corticosterone) from 
their inactive forms (cortisone or dehydrocorticosterone) (figure one). This reaction is 
catalysed by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an NADPH- 
dependent enzyme that abundantly expressed in the liver (Seckl and Walker, 2001). 
Activation of 11β-HSD1 results in the production of excess tissue glucocorticoids and 
induction of local glucocorticoid mediated alterations lipid metabolism leading to 
NAFLD in genetic and diet-induced laboratory animal models (Liu et al., 2005, 
Roberto et al., 2012). In contrast, reduction of 11β-HSD1 expression prevents 
regeneration of active glucocorticoids, and thereby reduces tissue glucocorticoid 
action, and increases insulin sensitivity in humans and laboratory animals 
(Hermanowski-Vosatka et al., 2005). More recently, pharmacological inhibition of 
11β-HSD1 has been shown to be effective and safe in reducing liver-fat content, 
suggesting that targeting 11β-HSD1 might be a promising approach for the treatment 
of NAFLD (Stefan et al., 2014). These studies point to the importance of 11β-HSD1- 
mediated regeneration of active glucocorticoids in the pathogenesis of NAFLD. 
Literature reports also suggest that the activity of 11β-HSD1 is stimulated by hexose- 
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6-phosphate dehydrogenase (H6PDH) located in the lumen of the ER, where it 
regenerates the NADPH required for 11β-HSD1 reductase activity (Chapman et al., 
2013). 
1.3.1 The role of 11β-HSD1 in the generation of active glucocorticoids 
 
As mentioned earlier, 11 beta-hydroxysteriod dehydrogenases are a microsomal 
enzyme complex that are NADPH dependent. As shown in figure 2, 11 beta- 
hydroxysteriod dehydrogenases catalyse the reversible conversion of cortisol to 
cortisone and has two isoforms; 11-HSD type-1 and 11 -HSD type-2 
(Hermanowski-Vosatka et al., 2005, Seckl, 2004, Cottrell and Seckl, 2009). Type-1 
and type-2 isozymes are found in many tissues in humans, particularly in the liver and 
kidney respectively. Studies show that although there are two isozymes they are 
primarily opposite in reaction direction in vivo, which is mainly driven by their 
intracellular location and accessibility of co-substrate. Therefore, 11-HSD 2 
inactivates the glucocorticoids and 11-HSD1 reactivates the glucocorticoids. 
Furthermore, because 11-HSD1 is classified as steroids, they are required to have a 
hydroxyl group at the C-11 position for it to have glucocorticoid and/or 
mineralocorticoid activity. It has an important role in regulating tissue exposure to 
active glucocorticoid due to its ability to catalyse the change between a hydroxyl and 
keto group at C-11 on the steroid (Cottrell and Seckl, 2009). There are various cells as 
well as immune cells that express 11-HSD1 and have a capacity to influence the local 
glucocorticoid availability whether it is within the individual cells or the whole tissues. 
There has been a number of reviews on the role of 11 beta hydroxysteriod 
dehydrogenase in the inflammatory response (Chapman et al., 2009, Chapman et al., 
2013, Chapman and Seckl, 2008, Cottrell and Seckl, 2009). 
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In vivo 11-HSD1 increases the glucocorticoid action and because the in the 
intact cells it predominantly oxo-reductase the reaction via catalyse by 11-HSD1. 
There are older studies that showed using non-selective inhibitors of 11-HSD to be 
interpreted in confounding by the predominant inhibition of renal glucocorticoids 
inactivation by 11-HSD2. Conversely, in the past decades the understanding of the 
role of 11-HSD1 in vivo has highly evolved by the disruption of the 11-HSD1 gene 
encoding in the generation of the mice homozygous (Cottrell and Seckl, 2009). There 
has been a number of studies on the phenotype of these mice including transgenic mice 
with tissue-specific modifications in 11-HSD1 (Cottrell and Seckl, 2009, Chapman 
et al., 2013, Holmes et al., 2006). In a review by Cottrell and Seckl in 2009, they found 
studies that showed basal plasma corticosterone levels are elevated in ob/ob mice, but 
they still displayed a consistent phenotype in the intracellular glucocorticoid 
deficiency. In some recent animal studies, there are mice that are generated which are 
deficient hexoe-6-phosphate dehydrogenase, as mentioned earlier it known as the 
regulator enzyme of 11-HSD1 which is found in the endoplasmic reticulum lumen 
(White et al., 2007, Cottrell and Seckl, 2009). For 11-HSD1 to function exclusively 
as a dehydrogenase and to inactivate glucocorticoids the normal reaction direction is 
reversed in mice with deficient H6PDH (White et al., 2007). Furthermore, there are 
similarities in the phenotypes in mice with deficient 11-HSD1 as they also cause 
alterations in glucose and lipid homeostasis and an increase in insulin sensitivity 
(Bujalska et al., 2008). In humans, there are evidence that support any mutations in the 
H6PDH gene are to be held responsible for cortisone reductase deficiency (White et 
al., 2007). 
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Figure 2. The catalytic action of the 11-HSD1 in the endoplasmic reticulum. 
 
 
 
 
1.3.2 Relevance of 11-HSD1 to NAFLD and Cushing’s syndrome 
 
In high fat diet consumption, the circulating glucocorticoids are increased, hence there 
is an upregulation of 11 beta dehydrocorticosterone (Chapman et al., 2009). Due to 
this upregulation, there are excess fat accumulation and multiple metabolic pathways 
are altered which lead to metabolic syndrome e.g. Cushing’s syndrome. 
Hypercortisolism, better known as Cushing’s syndrome is a disease as a result of 
disproportionate hormonal cortisol secretion from the adrenal glands (Kaye and Crapo, 
1990). As mentioned before, although the circulating amount in the body is necessary 
for the body functions, when it is present in excess, it can cause damage to the body. 
An overgrowth of the pituitary gland in the brain is the most common cause of 
Cushing’s disease (Kaye and Crapo, 1990). There is distinct visceral fat deposition 
caused by the excess production and release of glucocorticoids in Cushing’s syndrome 
(Morton, 2010). High accumulation of the visceral adiposity in the body has an 
increased rate of risk of cardiovascular-disease along with other fat related diseases 
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such as fatty liver disease (Morton, 2010). The expression of the glucocorticoid 
receptors is expressed in the visceral fat which is has higher impact on the metabolic 
responses as such insulin resistance and lipolysis and adipokine expression, reaching 
to the liver via their release through the portal vein (Morton, 2010). Research indicates 
that in Cushing’s syndrome the inhibition of AMPK’s activity of cellular energy sensor 
by glucocorticoids also contributes to fat depositions (Christ-Crain et al., 2008). 
1.4 Alcohol 
 
Conventionally, the term alcohol is used to refer to ethyl alcohol, mainly ethanol. The 
molecular formula of alcohol is C2H6O and the molecular weight of 46.07g/mol. It 
has a specific gravity of 0.785, it is colourless, volatile and is a flammable liquid. In 
alcoholic beverages it is the principal type of alcohol and the production is via 
fermentation of sugars by yeast. Ethanol has various industrial uses and it is a 
psychoactive drug and known as one of the oldest recreational drugs by humans. 
1.4.1 Pharmacokinetics of alcohol 
 
The pharmacokinetic properties of alcohol and the factors that effects the kinetic of 
alcohol are essential to understand as it is regularly used as recreational drugs that 
poses various health consequences. 
1.4.1.1 Absorption of alcohol 
 
Different type of administrations (oral and intravenous) determines the rate and 
quantity at which the consumed alcohol reached the blood and body tissues. In the 
small intestine and smaller extent in the stomach alcohol is generally absorbed by 
simple diffusion (Sadler, 2007). There are various factors involved in the rate of 
alcohol absorption, it is dependent on whether there was any consumption of food at 
the same time as alcohol and what type of macronutrients are within that food (Smart, 
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2007). There is a slow alcohol absorption with foods that contain fats and protein that 
slow gastric emptying, hence alcohol intake with these foods will result in slow 
absorption (Smart 2007). 
1.4.1.2 Distribution of alcohol 
 
There is a reduction in the bioavailability of alcohol by the first pass metabolism 
because the entrance of ethanol is the portal vein and the liver before it enters the 
general circulation. Alcohol dehydrogenase (ADH) oxidation pathway oxidases 
majority of alcohol. Gastric ADH oxidases a small percentage of alcohol in the gastric 
mucosa (Ferreira and Weems, 2008). Sadler et al (2007), highlights that if the alcohol 
absorbed by-pass the first pass metabolism it enters the systemic circulation. 
Furthermore, there is a rapid distribution of the absorbed alcohol in body tissues 
through the blood plasma. This occurs until an equilibrium is reached between the 
blood alcohol content and tissues concentration. A major influencing factor of the 
pharmacokinetics of alcohol is the total body water, as it is regulating the volume of 
alcohol distribution in the body. Hence, an imperative consideration in 
pharmacokinetic studies is the body composition and body size as it has a significant 
impact on the volume of distribution (Jones, 2007). 
1.4.1.3 Metabolism of alcohol 
 
The major organ for metabolising alcohol is liver and various studies report that ADH 
contributes to first pass metabolism. At physiological blood alcohol concentration in 
the liver, human ADH metabolises the alcohol inadequately. Nonetheless, in the first 
pass metabolism in the stomach it shows an important role as the molar range of gastric 
alcohol concentrations can be reached during alcohol consumption (Lee et al., 2003). 
Alcohol metabolism can occur in tissues that do not contain ADH, an example being 
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the brain where the enzyme cytochrome P450 metabolises and catalases. Moreover, 
both oxidative and non-oxidative pathways can be utilised to metabolise alcohol. 
1.4.1.4 Excretion of alcohol 
 
Alcohol metabolism performed by liver eliminates approximately 95% of ingested 
alcohol in the body. Urine, sweat, faeces and saliva are the different ways reminder of 
the alcohol in the body is eliminated. A number of different metabolic pathways is 
used by the body in the oxidation of alcohol to acetaldehyde to acetic acid to carbon 
dioxide and water (W and Suthat, 2006). There are several factors that influences the 
elimination of the alcohol. In healthy individual, one average drink of alcohol per hour 
is eliminated (W and Suthat, 2006). 
1.4.2 Pharmacodynamics of alcohol 
 
The frequency and quantity of alcohol consumption a dependant variable of the 
pharmacological effects. Several studies (table 1) provide evidence that light-to- 
moderate alcohol consumption produces benefits when compared to heavy alcohol 
consumption demonstrated toxics effects on the all the body systems. 
1.4.2.1 Standard drink and drinking patterns 
 
It is vital to have a distinct understanding of what establishes as a “standard drink” as it is 
important in clarification and application of alcohol guidelines. Currently, the Australian 
drinking guidelines outlines a standard drink includes 10g of alcohol which corresponds to 
12.5ml of alcohol. The conception of a standard drink is a worldwide issue as the definition 
of alters between different countries (NHaMR, 2001). Therefore, the alcohol drinking 
pattern is divided into 4 types: 
Light alcohol drinking: Alcohol intake is up to ONE standard drink per day (ONE 
Standard drink = 10 g of alcohol) by an average 60 kg adult. 
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Moderate alcohol drinking: Alcohol intake is up to TWO standard drinks per day by an 
average 60 kg adult. 
Heavy alcohol drinking: Alcohol intake is more than TWO standard drinks per day by 
an average 60 kg adult. 
Binge alcohol drinking: is alcohol intake up to FIVE or more standard alcohol drinks on 
a single occasion (NHaMR, 2001). 
1.4.3 Biological effects of light-to-moderate alcohol consumption 
 
A considerable amount of literature has been published (Table 1) on the evidence that 
highlight that light-to-moderate alcohol consumption have positive and protective 
actions on metabolic syndrome, type 2 diabetes (Bell et al., 2000, Greenfield et al., 
2003; Wannamethee et al., 2003), and cardiovascular diseases (Berger et al., 1999, 
Gaziano et al., 1993; Gaziano et al., 2000, (Beulens et al., 2007). 
1.4.3.1 Protective effects against metabolic syndrome 
 
As mentioned before, alcohol consumption in moderation may decrease the risk of 
metabolic syndrome. A 2004 study by a group of researchers showed that there was 
decrease in prevalence of metabolic syndrome in individuals who consumed alcoholic 
beverages when compared to non-alcoholic drinkers (Freiberg et al., 2004). Another 
study reported that if individuals consumed 1-15g of alcohol per day also showed a 
decrease in the prevalence of the metabolic syndrome (Yoon et al., 2004). In contrast, 
heavy alcohol consumption has an increased risk of metabolic syndrome and is mostly 
due to the contents and amount of alcohol in the heavy alcohol mix (Baik and Shin, 
2008). 
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1.4.3.2 Protective effects against type 2 diabetes 
 
An association can be implicated with the reduced risk of type 2 diabetes in individuals 
that are of normal weight or overweight and intake light to moderate alcohol. Yet, 
alcohol intake and risk of type 2 diabetes in obese individuals show no significant 
association. In 2001, a study by Hu et al., conducted over 16 years period showed a U- 
shape link between alcohol intake and risk of type 2 diabetes, with an inverse 
connotation was observed in individuals those were obese or overweight (Hu et al., 
2001). On the other hand, in 2003 Wannamethee et al., carried out similar studies and 
found that an inverse association between alcohol consumption and prevalence of type 
2 diabetes was observed in both obese/non-obese individuals. It is important to 
annotate that the inconsistencies can be due to the difference in drinking patterns or 
the quantity. Avogaro, A. et al., (2004) reports that both light and moderate alcohol 
consumption inhibit lipolysis which reduces the free fatty acids levels (Avogaro et al., 
2004). The protective effect of alcohol intake is mainly observed in overweight 
individuals where it perhaps responds to the obesity-induced insulin resistance. 
Assumptions are made that the reduction in insulin sensitivity may be facilitated 
through the influence of alcohol on the inflammatory pathway (Bell et al., 2000 and 
Greenfield et al., 2003). 
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Table 1. Literature summary of different types of studies that found protective 
effects of light and moderate alcohol. 
 
Type of Study Authors Findings 
Epidemiological 
studies 
Nova et al., 2012, Camargo et al., 
1997, Doll et al., 1994, Duffy, 1995, 
de Groot and Zock, 1998, Brenner, 
2000, Hoffmeister et al., 1999 
Light-to-moderate alcohol lowers the 
risk of mortality and morbidity of chronic 
diseases. 
Human studies Bell et al., 2000, Greenfield et al., 
2003 
 
 
Wannamethee et al., 2003 
 
 
Berger et al., 1999, Gaziano et al., 
1993, Gaziano et al., 2000 
Light-to-moderate alcohol lowers the risk 
of development of insulin resistance. 
 
 
Light-to-moderate    alcohol    lowers the 
risk of type 2 diabetes. 
 
 
Light-to-moderate alcohol protects 
against the risk of developing myocardial 
infarction and coronary artery disease in 
healthy populations. 
Animal Studies Nammi and Roufogalis, 2013; Feng 
et  al.,  2008;   Kanuri   et   al., 2016, 
Fromenty et al., 2009 
Light-to-moderate alcohol diminishes the 
development of NAFLD through 
improved liver lipid metabolism in 
normal and in high fat diet fed rats and in 
genetically obese rats. 
 
 
1.5 Gaps in literature 
 
Non-alcoholic fatty liver disease and other metabolic disorders such as obesity, insulin 
resistance and Cushing’s syndrome are results from high-fat diet, poor lifestyle 
choices, genetics or pre-existing metabolic syndromes. As mentioned in the literature 
review, with high-fat diet and excess glucocorticoids lead to excess fat accumulation 
in the body. Thereby, causing multiple diseases. Thus, it is essential to build on the 
knowledge from the protein level, enabling better understanding in what mechanism(s) 
is/ are used to cause these diseases. Although, alcohol is mainly used as a recreational 
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drug. Alcohol intake has various physiological effects on the organs that is dose 
dependent. There are a number of evidence that suggest protective effects of light to 
moderate alcohol consumption on various diseases such as cardiovascular disease, 
diabetes and metabolic diseases. There are only a couple of studies done on the effects 
of light to moderate alcohol consumption on the excess glucocorticoids when exposed 
prenatally, but it did not include the high-fat diet groups. Therefore, with the increasing 
prevalence of obesity which leads to and increase prevalence in NAFLD, it is 
important to find the exact protective mechanism involved in the up or downregulation 
of the excess glucocorticoids. 
1.6 Hypothesis and objectives of the thesis 
 
In this project, we hypothesize that light-to-moderate alcohol consumption prevents 
the development of NAFLD by down-regulating the expression of 11β-HSD1 in the 
liver. Thus, we investigated whether light-to-moderate alcohol feeding in high-fat diet- 
fed rats protects from NAFLD by inhibiting the 11β-HSD1-mediated interconversion 
of glucocorticoids in the liver with three specific objectives. 
Objective 1: To investigate effects of light and moderate alcohol treatment on protein 
expression of 11β-HSD1 in the liver of HFD-fed rats. 
Objective 2: To investigate the effects of light and moderate alcohol treatment on the 
enzyme activity of 11β-HSD1 in the liver of HFD-fed rats. 
Objective 3: To study the effects of light and moderate alcohol treatment on serum and 
liver corticosterone levels in HFD-fed rats. 
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2.1 Chemicals used 
 
Ethanol (98%), Tris base, SDS, Glycine, Methanol, NaCl, Acrylamide/bi-acrylamide 
(30%), EDTA, EGTA, Sucrose, Triton X-100, BSA standards, Glycerol (40%), 
Sodium phosphate monobasic and dibasic, ECL reagents, Tween 20 was purchased 
from Sigma-Aldrich Pty Ltd (Sydney Australia), NADPH was purchased from Astral 
Scientific (Sydney, Australia), 11 dehyrocorticosterone was purchased from Jomar 
Life Research (Victoria, Australia), 11 beta hydroxysteriod dehydrogenase antibody 
was purchased from Astral Scientific (Sydney, Australia), Bio-Rad assay dye reagent 
concentrate, Laemmli Buffer and Protein Standard-Stained was purchased from Bio- 
Rad Laboratories Pty Ltd (Sydney, Australia), Corticosterone EIA and ELISA kit was 
purchased from Cayman Chemicals (USA), Protease and Phosphatase inhibitors was 
purchased from Bio-Rad. 
2.2 Equipment used 
 
Bio-Rad electrophoresis chambers, Bio-Rad gel plates and gel stands, Analytical 
weighing balance (Mettler Toledo), bench top centrifuge (5424 Eppendorf), cooling 
centrifuge (5810 Eppendorf), incubator (Thermo Scientific), pH meter (3505 J 
Enway), vortex mixer (Stuart), water bath (Stuart), magnetic stirrers (IKA), Bio-Rad 
Spectrophotometer (Bio-Rad), Dry heating block, Carestream gel logic pro 2200, the 
homogenising tool Shaker were used in this study. 
2.3 Preparation of reagents 
 
2.3.1 Running gel buffer 
 
To 500 mL of deionised water, 90.82 g of Tris base, 2 g of SDS was added in a 
volumetric flask and mixed well using a magnetic stirrer. The solution was transferred 
into a beaker and the pH was adjusted to 8.8 and stored at room temperature. 
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2.3.2 Stacking gel buffer 
 
To 250 mL of deionised water, 15.14 g of tris-base and 1g of SDS was added in a 
volumetric flask and mixed well using a magnetic stirrer. The solution was transferred 
into a beaker and the pH was adjusted to 6.8 and stored at room temperature. 
2.3.3 Running gel buffer (10x) 
 
To 800 mL of deionised water, 144.4 g of glycine, 30.3 g of tris-base, and 10 g of SDS 
was added in a volumetric flask and mixed well using a magnetic stirrer. The solution 
was then transferred into a beaker, the pH was adjusted to 8.3 and the volume was 
made up to 1000 mL and stored at 4C. Working running buffer (1x) was prepared 
fresh daily prior to the experiment; briefly, 100 mL of 10x running buffer was added 
to 900 mL deionised water and mixed well. 
2.3.4 Transfer buffer (10x) 
 
To 800 mL of deionised water, 3.03g of tris-base and 14.41g of glycine was accurately 
weighed and added in a volumetric flask and mixed well using a magnetic stirrer. The 
volume was made up to 1000 mL by the addition of 200 mL methanol and stored at 
-20 C. This solution was made fresh prior the experiment. 
 
2.3.5. Tris-buffered saline (TBS; 10x) 
 
To 800 mL of deionised water, accurately weighed out 24.2 g of tris-base and 80 g of 
NaCl was added in a volumetric flask and mixed well using a magnetic stirrer. The 
solution was transferred in to a beaker , the pH was adjusted to 7.6 and the volume was 
made up to 1000 mL and stored at 4C. Working TBS (1x) was prepared daily for use; 
briefly, 100 mL of 10x TBS was added to 800 mL of deionised water, 1 mL of Tween 
20 was added and the volume was adjusted to 1000 mL and mixed well. 
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2.3.6. Phosphate-buffered saline (PBS; 1x) 
 
To 800 mL of deionised water, 8 g of NaCl, 0.2 g of KCl, 1.44 g of Na2HPO4, 0.24 g 
of KH2PO4 was accurately weighed and added in to a volumetric flask and mixed well 
using a magnetic stirrer. The solution was then transferred into a beaker, the pH was 
adjusted to 7.4 and the volume was made up to 1000 mL and stored at 4C. 
2.3.7. Sodium phosphate buffer (50mM) 
 
To 100 mL of deionised water, accurately weighed out 6.89 g of sodium phosphate 
monobasic and 7.09 g of sodium phosphate dibasic, 1mM EDTA (final concentration), 
1M NaCl (final concentration), 40% (wt/vol) glycerol (final concentration) and 0.4% 
triton X-100 (final concentration) was added in a volumetric flask and mixed well 
using a magnetic stirrer. The solution was then transferred into the beaker, the pH was 
adjusted to 7.4 and stored at 4C. 
2.3.8 NADPH stock (24mM) 
 
To 1 mL of deionised water, accurately weighed 0.020 g of NADPH was added in a 2 
mL Eppendorf tube and mixed well via vortex and stored at 4C. 
2.3.9 11-dehydrocorticosterone stock (10mM) 
 
To 1 mL of 50% ethanol, accurately weighed 3.44 g of 11-dehydrocorticosterone and 
was added in a 2 mL Eppendorf tube and mixed well via vortex and stored at 4C. 
2.3.10 Homogenising buffer 
 
To 200 mL of deionised water, accurately weighed out 20mM of Tris-base (0.6 g), 
1mM of EDTA (0.1 g), 0.5mM of EGTA (0.47 g), 250mM sucrose (2.12 g), 0.1% of 
Triton X-100 (250 L), 100 L of protease and phosphatase inhibitors (was added 
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prior the experiment) was added in volumetric flask and mixed well using a magnetic 
stirrer. The solution was then transferred into the beaker and the pH was adjusted to 
7.6 and stored at 4C. 
 
2.3.11 Preparation of the ELISA Reagents 
 
The preparation of ELISA reagents was made following the manufacturer’s 
instructions and is outlined in the following subsections. 
2.3.11.1 ELISA buffer 
 
The contents of one vial (10 mL) of 10X ELISA buffer was diluted in a volumetric 
flask with 90 mL of ultrapure water and the solution was mixed well using a magnetic 
stirrer and stored at 4C. 
2.3.11.2 Wash buffer 
 
The contents of one vial (5 mL) of 400X wash buffer was diluted to two litres with 
ultrapure water and 1 mL of Polysorbate 20 was added in volumetric flask and mixed 
well using a magnetic stirrer. The solution was stored at 4C. 
2.3.11.3 Corticosterone AChE tracer 
 
The 100 dtn corticosterone AChE tracer was reconstituted with 6 mL of ELISA buffer 
in a 15 mL falcon tube and was vortexed to mix well. The solution was stored at 4C. 
2.3.11.4 Corticosterone ELISA antiserum 
 
The 100dtn corticosterone ELISA antiserum was reconstituted with 6 mL of ELISA 
buffer in a 15 mL falcon tube and was vortexed to mix well. The solution was stored 
at 4C. 
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2.3.11.5 Ellman's reagent 
 
The 100 dtn vial of Ellman’s reagent was reconstituted with 20 mL of ultrapure water 
in a 15 mL falcon tube and was vortexed to mix well. This solution was prepared 
immediately prior use in the ELISA procedure. 
2.4 Dosage selection of the treatment and sample size 
 
2.4.1 Dosage selection 
 
The dosage selection and conversion human dose of ethanol to animal used in this 
experiment is performed based on the formula conveyed by Reagan-Shaw, Nihal & 
Ahmad in 2008. The Km factor defined as body weight in kilograms divided by body 
surface area (m2). 
Km value for rat= 6; Km value for human =37 
 
Moderate alcohol consumption level in humans as per NHMRC guide lines for an 
average human weighing 60 kg is 20 grams/day which is equivalent to 330 mg/kg/day. 
330=X*6/37 
X= 330*37/6 
X= 2035 mg/kg/day 
= 2 g/kg/day 
Thus, 2 g/kg/day is used as the equivalent dose of ethanol in representation of moderate 
consumption in rats. 
Light alcohol consumption level in humans as per NHMRC guide lines for an average 
human weighing 60 kg is 10 grams/day which is equivalent to 165 mg/kg/day. 
165=X*6/37 
X= 165*37/6 
X= 1017.5 mg/kg/day 
= 1 g/kg/day 
Thus, 1 g/kg/day is used as the equivalent dose of ethanol in representation light 
consumption in rats. 
30 
Chapter 2: Materials and Methods| Shayal Devi 17726317 
 
 
 
2.4.2 Sample size 
 
There are two methods that animal studies sample size can used. The well-known and 
preferred method is the calculation by power analysis. If information about standard 
deviation, effective size, survival rate, etc. is not available, the possibility to perform 
power calculation is none. In this case, an alternative method commonly called as 
“resource equation method” can be used (Festing & Altman 2002). In this method, a 
value ‘E’ that indicates the sample size is measured which is nothing but the degrees 
of freedom of analysis of variance (ANOVA). The ‘E’ value is calculated by 
subtracting the total number of experimental groups from the total number of 
experimental animals and inferences made as given in the below table 2. 
Table 2. Resource equation method for sample size determination 
 
E value Conclusion 
E< 10 Sample size should be increased 
E>20 Sample size should be decreased 
10<E< 20 Optimum sample size 
E = Total number of animals - Total number of groups 
 
In this study, the number of experimental groups are 4 and the total number of 
experimental rats are 24. Therefore, by using the above formula the calculated E value 
is: 
E = Total number of animals - Total number of groups 
E = 24 - 4 
E = 20 
 
Hence, the number of rats in each group (n=6) represent adequate sample size. 
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2.5 Evaluation of the effects of light and moderate alcohol in high fat diet-fed rats 
(in vivo studies) 
Adult male Sprague-Dawley rats was obtained from the Animal Resources Centre, 
WA, Australia. All procedures that involved animals was conducted in accordance 
with the terms of the Institutional Animal Ethics Committee of the Western Sydney 
University (Approved Protocol Number A9387]. 
The high fat diet (HFD)-fed rat model was a well characterized and established 
model that simulated the common manifestations of human metabolic syndrome and 
developed NAFLD (Panchal et al., 2011). The effect of light and moderate alcohol was 
studied for 15 weeks in separate groups of rats. The rats were given ethanol by oral 
gavage twice daily at 9 am and 5 pm for 15 weeks as per the following design: Group 
1 (light ethanol) were treated with 6% ethanol (v/v) at a dose of 10 ml/kg body weight 
(equivalent to 0.5 g/kg) and were fed with HFD; Group 2 (moderate ethanol) were 
treated with 12% ethanol (v/v) at a dose of 10 ml/kg body weight (equivalent to 1g/kg) 
and were fed with HFD; Groups 3 (Normal control) and 4 (Disease control) were 
treated with similar volumes of distilled water and were respectively fed with standard 
pellet diet or HFD. Thus, the daily intake of ethanol received by the light and moderate 
ethanol groups will be 1g/kg/day and 2 g/kg/day respectively. These are the animal 
dose equivalents to the corresponding human doses that reflect one (light drinking) 
and two (moderate drinking) standard drinks respectively. Blood sampling was done 
at weekly intervals, the serum was separated and stored at -20 C for serum analysis. 
At the end of 15 weeks, the rats were euthanized, and the livers were dissected out and 
stored at -80C for cellular and molecular investigations. 
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2.5.1 The effects of light and moderate alcohol treatment on protein expression of 
11β-HSD1 in the liver of HFD-fed rats 
2.5.1.1 Liver protein extraction 
 
Frozen liver samples were placed on ice for thawing and it remained on ice for the rest 
of this procedure. Weighed out approximately 100-150 mg using the scale, the liver 
was cut using the surgical forceps and scissors were used to cut out small piece. The 
weighed samples then were washed in 1X PBS without any damage or tissue loss and 
transferred in labelled test tubes. Based on the weight of the sample, 5 times the volume 
of homogenising buffer (if the sample weighed 150mg, volume of the homogenising 
buffer was 750 L) was added. After the addition of the buffer the tissues were 
homogenised using the homogenising tool. The homogenate was then transferred into 
Eppendorf tubes and centrifuged at 1500 RPM for 10 minutes at 4C. The supernatant 
was obtained, and protein estimation of the samples was performed as described in the 
below section. 
2.5.1.2 Protein estimation using bovine serum albumin (BSA) as a standard 
 
The Bio-Rad BSA standard procedure with slight modifications made in general 
laboratory procedure is used to determine the BSA standards curve. The protein 
estimations of the samples were determined using the BSA standard curve. To 40 mL 
of deionised water, 40 mg of BSA was accurately weighed and mixed in a volumetric 
flask to prepare BSA stock solution. The following working BSA standards were then 
made as shown in table 3. 
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Table 3. Construction of BSA standard curve 
 
 
Working BSA standard 
(mg/mL) 
Stock BSA (mL) Deionised water (mL) 
0 NA 1000l 
0.2 200l 800l 
0.4 400l 600l 
0.6 600l 400l 
0.8 800l 200l 
1 1000l NA 
 
 
 
After the dilutions were made, it was mixed well via vortex and plated in duplication 
on a 96 well plate. To 10l of different BSA concentrations, 200l of Bradford protein 
assay reagent was added. It was then incubated for 10 minutes at 37 °C. The 
absorbance was read at 595 nm in a spectrophotometer. The standard curve was 
prepared to find the concentration of total protein in each liver supernatant. 
2.5.1.3 Western blot analysis 
 
The western blot samples were prepared based on Nammi et al., 2007 with slight 
modifications. Briefly, the liver sample supernatant was made into small aliquots of 
20l. These samples were diluted 2X with homogenising buffer, and further diluted 
2X with Laemlli buffer, prior denaturing the protein by dry block heating for 5 mins 
at 95C. The samples were then brought to room temperature prior loading it on the 
SDS-PAGE gel. 
34 
Chapter 2: Materials and Methods| Shayal Devi 17726317 
 
 
 
In duplication, each sample were loaded with 50μg of total protein and were 
electrophorectically resolved on 8% SDS-PAGE gels at 30V for 15 minutes and 135V 
for 1 hour and 15 minutes and then transferred for at 100V for 2 hours onto a 
nitrocellulose membrane by using wet transfer. After blotting, the membranes were 
blocked with 5% non-fat dry milk in 1X Tris-buffered saline- 0.1% Tween-20 (TBST, 
pH 7.6) at room temperature for 1 hour on shaker. The membranes were then washed 
three times for 10 mins each with TBST. And it was incubated overnight at 4°C on 
shaker with primary antibody for monoclonal anti-rabbit 11-beta hydroxysteriod 
dehydrogenase (1:1000) diluted with 1X TBST. The next day, the blots were washed 
again three times for 10 minutes each with 1X TBST and incubated for 1 hour at room 
temperature with anti-rabbit secondary antibody at 1: 10,000 dilutions with PBS, pH 
7.4. The membranes were washed again for three times for 10 minutes each with TBST 
and incubated with Enhanced Chemiluminescence reagent (Bio-Rad) for 1 minute at 
room temperature. The membranes were then imaged using Carestream gel logic pro 
2200 under white light epi-illumination. Quantitative image analysis was performed 
using NIH Image software (Image J) to determine the intensity of the protein signal, 
which was expressed relative to the amount of β-actin used as an internal control. 
2.5.2 The effects of light and moderate alcohol treatment on the enzyme activity of 
11β-HSD1 in the liver of HFD-fed rats 
 
2.5.2.1 11β-HSD1 enzyme activity assay 
 
As described in Section 2.5.1, the frozen liver samples were homogenised, and the 
supernatant taken for the oxo-reductase enzyme activity of 11 beta hydroxsetriod 
dehydrogenase. The samples were prepared according to Nammi et al., 2007. Briefly, 
in an Eppendorf tube, 20l of 50mM sodium phosphate buffer (pH 7.4) containing 
6.89g of sodium phosphate monobasic and 7.09g of sodium phosphate dibasic, 1mM 
EDTA (final concentration), 1M NaCl (final concentration), 40% (wt/vol) glycerol 
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(final concentration) and 0.4% triton X-100 (final concentration), 10l of 2.4mM 
NADPH and 10l of 1mM 11 dehyrocorticosterone was added and incubated for 3 
minutes at 37C. After the incubation, the reaction was started by adding 60l of the 
sample tissue extracts (0.5 to 1.0 mg protein) and was incubated for one hour at 37C. 
The reaction was terminated by dipping the tubes immediately into ice, and 
corticosterone was determined using EIA corticosterone kit as detailed in the below 
section following manufacturer’s instructions. Blanks were tubes where neither 
NADPH nor 11-dehydrocorticosterone were added. Specific activities were expressed 
as picograms of corticosterone formed per minute per milligram of protein. 
2.5.2.2 Enzyme-immunoassay of corticosterone 
 
Equilibrated the pipette tip with ethanol by filling and expelling the tip with ethanol 
several times. Transferred 100l of corticosterone ELISA Standard in to a clean test 
tube, then diluted with 900l ultrapure water. The final concentration of this solution 
was 50ng/ml. Eight concentrations ranging from 0.012-5 ng/ml was used as the 
standard. 
Serial dilutions of the corticosterone ELISA standard were performed, briefly; 
added 900l of ELISA buffer to tube 1 and 750l ELISA buffer to tubes 2-8. Then 
transferred 100l of the bulk standard (50ng/ml) to tube 1 and mixed thoroughly via 
vortex. Then further diluted the standard by removing 500l from tube 1 and placed it 
to tube 2 and mixed thoroughly via vortex. Then removed 500l from tube 2 and 
placed it into tube 3 and mixed thoroughly. This step was repeated for tubes 4-8. 
In the procedure the pipette tips were equilibrated the same way as described 
earlier. In non-specific binding (NSB) wells and maximum binding (BO) wells, 100l 
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and 50l of ELISA buffer was added respectively. In duplication, started from the 
lowest to highest concentrations of the corticosterone ELISA standard, 50l was 
added. Followed triplication plating of 50l of liver samples in each well. Excluding 
the total activity and blank wells, 50l of corticosterone AChE tracer was added to 
wells with ELISA standards, NSB, BO and serum samples. Followed by 50l of 
corticosterone ELISA antiserum in wells, excluding the total activity, blank and NSB 
wells. The plate was covered with foil and then incubated overnight at 4°C. The next 
day, the plates were developed by emptying the wells and rinsed five times with the 
wash buffer. To each well, 200l of Ellman’s reagents was added. Followed by 5l of 
corticosterone AChE tracer in the total activity well. The plate was then left for 
development for 120 minutes and it was covered with foil (as it needed darkness to 
develop) and for optimum development, an orbital shaker was used. After the plate 
was developed, the foil was removed carefully, and the bottom of the plate was wiped 
with Kim wipes in order to remove any fingerprints or dirt. The plate was read using 
the spectrophotometer at the wave length of 412 nm. 
2.5.3 The effects of light and moderate alcohol treatment on serum and liver 
corticosterone levels in HFD-fed rats 
2.5.3.1 Serum and liver samples 
 
The corticosterone levels in the serum and liver were measured to determine the effects 
of light and moderate alcohol in all four groups of experimental rats. After the 
collection of the blood samples, they were kept on ice undisturbed for clotting for 20 
minutes. It was then followed by 3,000 rpm centrifugation in 4°C. After the serum was 
separated, it was carefully collected and placed in individual falcon tubes and stored 
at -20°C for analysis. The liver samples were the same homogenate as enzyme activity 
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samples. The supernatant was taken for measurement for serum and liver 
corticosterone using enzyme-linked immunoassay as detailed in Section 2.5.2.2. 
2.5.4 Data and statistical analysis 
 
Data are expressed as mean  standard error of means. Statistical analysis was done 
using one-way analysis of variance (ANOVA) followed by post hoc Dunnet’s test 
using Graph Pad Prism software (Version 5.0). In all tests, p<0.05 was used as the 
criterion for statistical significance. 
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3.1 The effects of light and moderate alcohol treatment on the protein expression 
of 11β-HSD1 in the liver of HFD-fed rats 
 
The protein expression of 11-HSD1 as determined by Western blot analysis in the 
liver of HFD-fed rats is shown in Figure 3. After 15 weeks of high-fat diet 
consumption, 11-HSD1 protein was significantly (p<0.05) increased in the HFD-fed 
(n=6) rats when compared to normal control (n=5) with an increase of 1.7-fold. 
Treatment of high-fat diet-rats with light alcohol (1g/ml/day; n=5), showed a 
significant (p<0.05) decrease in 11-HSD1 protein by 1.6- fold when compared to the 
HFD-fed rats. Interestingly, 11-HSD1 protein in HFD-fed rats treated with moderate 
alcohol (2g/ml/day; n=6), showed a significant (p<0.01) decrease by 2 folds. 
 
 
Figure 3. The protein expression of 11 hydroxysteriod dehydrogenase (11-HSD1) in the liver. 
Western blot analysis of liver in HFD fed-rats, normal control and with light-to-moderate alcohol 
treatment (n=5-6/group) was used to determine 11-HSD1 protein. A representative blot is shown for 
each group of rats studied, at 36 kDa for 11-HSD1. The protein concentrations of 11-HSD1 in the 
individual groups are expressed in arbitrary units relative to -actin. Significant difference from normal 
control group: # P<0.05. Significant difference from HFD control: * P<0.05; ** P<0.01. 
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3.2 Effects of light and moderate alcohol treatment on the enzyme activity of 11β- 
HSD1 in the liver of HFD-fed rats 
 
The effects of light-to-moderate alcohol treatment on NADPH-dependent oxo- 
reductase enzyme activity of 11-HSD1 was studied in HFD-fed rats (Figure 4). A 
significant (P<0.01) increase of the oxo-reductase activity (2.5 fold) in the HFD-fed 
rats was observed compared to normal control. On the other hand, a significant 
(P<0.05) decrease of the enzyme activity in the light alcohol treatment group compared 
to the HFD control was observed. In parallel, a significant (P<0.001) decrease in oxo- 
reductase activity in the moderate alcohol treatment group compared to the HFD 
control was observed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Oxo-reductase activity of 11β-HSD1 in liver. The 11β-HSD1 reductase activity was measured 
in whole liver extracts with the use of 11-dehyrocorticosterone as substrate with NADPH in the HFD- 
fed rats. The figure shows the enzyme activity reduction in the treatment groups when compared to the 
disease control. Data are presented as means ± SEM. Significant difference from normal control group: 
## P<0.01. Significant difference from HFD control: * P<0.05; ** P<0.01. 
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3.3 Effects of light and moderate alcohol treatment on serum and liver 
corticosterone levels in HFD-fed rats 
 
Figure 5A shows the serum and liver corticosterone in the different experimental 
groups of rats. The liver corticosterone concentrations were more than the serum 
corticosterone concentrations by 6-8 fold. In the serum, there is a significant (P<0.05) 
increase of corticosterone in the HDF control group when compared to normal control. 
A significant decrease in serum corticosterone was observed in the light (P<0.05) and 
moderate (P<0.01) treatment groups when compared with the HFD control rats. 
As shown in Figure 5B, corticosterone levels were significantly (P<0.01) 
elevated in the HFD rats compared with the normal control. In consistent with the 
serum measurements, the corticosterone levels in the light (P<0.05) and moderate 
(P<0.01) treatment rats were significantly decreased compared with the HFD rats. 
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Figure 5. Serum (A) and liver (B) corticosterone levels as measured by enzyme-linked immunoassay 
(EIA) in the serum and liver of HFD-fed rats alone or with light or moderate alcohol. The data are 
shown as means ± SEM. Significant difference from normal control group: # P<0.05; ## P<0.01. 
Significant difference from HFD control: * P<0.05; ** P<0.01. 
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The present study was designed to determine the effect of light-to-moderate alcohol 
consumption on the regulation of 11β-HSD1 protein expression and enzyme activity 
in liver of high fat diet-fed rats. To our knowledge, this is the first study to demonstrate 
an effect of chronic light-to-moderate alcohol consumption on the hepatic regulation 
of 11β-HSD1 which has been implicated in glucocorticoid excess and in the 
development of metabolic syndrome and NAFLD. 
 
In humans, increased 11β-HSD1 expression is known to be important for the 
pathogenesis of the metabolic syndromes such as the obesity and Cushing’s syndromes 
(Seckl and Walker, 2001). Overexpression of 11β-HSD1 in transgenic mice, mainly in 
the adipocytes leads to increased adipose levels of corticosterone and development of 
metabolic syndrome, visceral obesity and insulin resistance (Masuzaki et al., 2001). 
Although no changes of gluconeogenic enzymes are evident, increased expression of 
11β-HSD1, mainly in the mice liver, causes fatty liver, dyslipidaemia and insulin 
resistance (Masuzaki et al., 2001). In obese individuals, the 11β-HSD1 activity is 
increased at the tissue level (McCormick et al., 2006). Similarly, in animal studies, the 
high-fat-diet induced obese rats show an elevated 11β-HSD1 expression in the liver 
when compared to normal control groups (Song et al., 2017, Peng et al., 2016). A 
considerable amount of literature has been published on the evidence that highlight 
that light-to-moderate alcohol consumption have positive and protective actions on 
metabolic syndrome, type 2 diabetes (Bell et al., 2000, Greenfield et al., 2003; 
Wannamethee et al., 2003), and cardiovascular diseases (Berger et al., 1999, Gaziano 
et al., 1993; Gaziano et al., 2000, (Beulens et al., 2007). In this study, high fat diet 
feeding in rats increased the expression of 11β-HSD1 protein in the liver consistent 
with earlier reports highlighting that excess fat consumption increases 11β-HSD1 levels 
in the liver. (Song et al., 2017, Peng et al., 2016). Therefore, inhibition of 
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11β-HSD1 protein expression is recommended to stop excess fat accumulation which 
leads to serve diseases such as NAFLD (Hermanowski-Vosatka et al., 2005, Sanna et 
al., 2016, Stefan et al., 2014). 
 
In vivo 11-HSD1 increases the glucocorticoid action and because in the intact 
cells it predominantly oxo-reductase the reaction via catalyse by 11-HSD1. The 
NADPH-to-NADP ratio is an important regulator of the 11β-HSD1 reaction direction 
determined by the kinetic study. In this study, we found a quantifiable amount of 11β-
HSD1 oxo-reductase activity in tissue homogenates of liver. In this study, a high value 
of enzymatic activity of 11β-HSD1 is present in the liver. As other reports show higher 
expression of 11β-HSD1 in the liver when compared to other tissues (Walker et al., 
2003). Furthermore, this study used 11β-HSD1 dehydrogenase assay. In a study by 
Bujalska et al., used the 11β-HSD1 dehydrogenase and reductase assays in adipocytes 
and found after the engagement with glucocorticoids and differentiation in insulin and 
subsequent there was an increase of 11β-HSD1 reductase, but the dehydrogenase 
neither showed an increase or decrease. 
 
Number of studies suggest that glucocorticoids through their receptors play an 
essential role in the development of types 2 diabetes. The increased production hepatic 
glucose and proliferation/differentiation of the adipocytes are increased by the 
glucocorticoid. Thus, leads to the pathogenesis of the metabolic syndrome (Hauner et 
al., 1989, Pilkis and Granner, 1992). In patients with Cushing’s syndrome, there is a 
manifestation metabolic syndrome such as visceral fat, diabetes, insulin resistance and 
dyslipidaemia which can also be found in the genetically obese rodents with high 
production of glucocorticoids (Björntorp and Rosmond, 2000). In previous reviews, 
they found that mice that displayed a consistent phenotype of intracellular 
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glucocorticoids deficiency, also displayed the basal plasma corticosterone levels were 
elevated (Seckl, 2004, Cottrell and Seckl, 2009). Whereas in the present study, serum 
corticosterone concentrations were of less value then the liver corticosterone 
concentrations in HFD control group. Moderate alcohol treatment decreased the levels 
of corticosterone in both serum and liver when compared to the HFD-fed rats. 
Moreover, the liver tissue extract had the higher value of corticosterone indicates it is 
increased by the local factors involved in the manifestation of hypercorticolism. 
 
In conclusion, the present study demonstrated that chronic light-moderate 
alcohol consumption down-regulated 11β-HSD1 protein expression and decreased 
enzymatic activity in the liver of HFD-fed rats, which was associated with a reduction 
in circulating and liver corticosterone levels. Thus, the present study provides 
mechanistic evidence for the earlier epidemiological studies that indicate light-to- 
moderate alcohol consumption lowers the risk of development of metabolic syndrome 
leading to NAFLD, at least in part, via targeting 11β-HSD1. 
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5.1 Conclusions 
 
• High fat diet (HFD) feeding for 15 weeks increased both circulating and liver 
corticosterone levels in rats. 
• Chronic light-to-moderate alcohol treatment decreased both circulating and liver 
corticosterone levels in rats fed with high fat diet. 
• HFD feeding for 15 weeks up-regulated the protein expression 11β-HSD1 in the liver 
of rats. 
• Chronic light-to-moderate alcohol treatment prevented the HFD-induced enhancement 
of 11β-HSD1 protein expression in the liver of rats. 
• HFD feeding for 15 weeks increased the enzyme activity of 11β-HSD1 in the liver of 
rats. 
• Chronic light-to-moderate alcohol treatment reduced the enzyme activity of 11β-HSD1 
in the liver of rats. 
 
 
 
5.1 Limitations and Future directions 
 
In the present study, the effect of light-to-moderate alcohol on the regulation of 11β-HSD1 is 
only studied at the protein level due to time and budgetary constraints. Future studies along 
these lines could be investigated on the regulation of 11β-HSD1 at the mRNA level in order to 
unravel whether the down-regulation of 11β-HSD1 with light-to-moderate alcohol treatment 
occurs at the transcriptional level. Furthermore, H6PDH – an enzyme that closes associates 
with 11β-HSD1 was not studied in the present investigation, which is worthwhile to measure 
in future to demonstrate the cross-talk mechanisms of these important enzymes involved in the 
positive effects of light-to-moderate alcohol on metabolic syndrome induced by high fat diet. 
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